NYC-based FCB Health appointed Kim Barke to the role of group creative director to lead its oncology accounts.
Being born at below-normal weight is associated with a lower intelligence quotient (IQ) not only in childhood and young adulthood, but even at age 50, according to a new study from Denmark.
Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.
India’s drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval.
More than a dozen Democratic attorneys general sought to intervene to defend a key part of the Obamacare healthcare law – subsidy payments to insurance companies – which is under threat in a court case.
Rockville, Mary.-based GlycoMimetics’ shares jumped dramatically on the news of positive interim Phase II data for GMI-1271 for acute myeloid leukemia.
As Teva Pharmaceutical narrows down its candidate for a new chief executive officer, the company is shuttering a plant in Hungary and laying off 500 employees, according to reports.
Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.
FDA Approves Kalydeco for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Concert Pharmaceuticals Inc. said the U.S. FDA imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.
India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.
More than half of all deaths have no recorded cause, making effective health monitoring and policymaking far more difficult, the World Health Organization (WHO) said.
In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.
Amazon is reportedly looking for a new venture – in the pharmaceutical market. CNBC reported that for the past few years the company has been exploring the multi-billion industry, but has not yet made a move. However, that appears to be changing.
German drugmaker Bayer won the U.S. Food and Drug Administration’s priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.
Johnson & Johnson is required to add new warnings to its diabetes drug Invokana about the risk of foot and leg amputations, the U.S. Food and Drug Administration said.
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States.
Danish drugmaker Novo Nordisk said the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to “a potential conflict of interest.”
What if a single smartphone app could help solve the enigma of multiple sclerosis (MS) and move new treatments ahead at lightning speed? That was the bold idea that led Keck Medicine of USC neurologist Daniel Pelletier, MD, professor of neurology at the Keck School of Medicine of USC and division chief of the Neuro-Immunology and USC Multiple Sclerosis Center, to develop myMS – the world’s first smartphone app capable of collecting large amounts of clinical, imaging and genetic data for people with MS. Enrollment is now under way for a pilot study of the app.